Search clinical trials for: YM060

Total 10 results

Astellas Pharma Inc

Completed

Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Irritable Bowel Syndrome

Poland, Germany, Bulgaria, Ukraine, Estonia, Russian Federation, Czech Republic, Lithuania
Astellas Pharma Inc

Completed

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake

Healthy | Plasma Concentration of YM060

Japan
Astellas Pharma Inc

Completed

Special Drug Use Surveillance of Irribow in Female Patients

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Healthy | Plasma Concentration of YM060

Japan
Astellas Pharma Inc

Completed

A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients

Irritable Bowel Syndrome

Japan

3

Subscribe